Treatment of type 2 diabetes mellitus patients
The present invention refers to lixisenatide for use in the reduction of progression of urinary albumin excretion in a type 2 diabetes mellitus patient.
1. A method of reducing urinary albumin excretion in a type 2 diabetes mellitus patient with albumunuria, said method comprising
selecting a type 2 diabetes mellitus patient with albuminuria, and administering lixisenatide or a pharmaceutically acceptable salt thereof to the patient in need thereof, thereby reducing albumin excretion in the patient.
2. The method of claim 1 , wherein the patient has microalbuminuria.
3. The method of claim 1 , wherein the patient has a urinary albumin to creatinine ratio (UACR) of ≥30 mg/g to <300 mg/g.
4. The method of claim 1 , wherein the patient has a urinary albumin to creatinine ratio (UACR) of ≥300 mg/g.
5. The method of claim 1 , wherein the patient has a glomerular filtration rate (GFR) of ≥60 mL/min/1.73 m 2 to <90 mL/min/1.73 m 2 .
6. The method of claim 1 , wherein the patient has a glomerular filtration rate (GFR) of ≥30 mL/min/1.73 m 2 to <60 mL/min/1.73 m 2 .
7. The method of claim 1 , wherein the patient has a glomerular filtration rate (GFR) of ≥15 mL/min/1.73 m 2 to <30 mL/min/1.73 m 2 .
8. The method of claim 1 , wherein the patient receives lixisenatide in combination with
an insulin or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein prior to the onset of treatment with lixisenatide, the patient has a HbA1c value of 7% to 10%.
10. The method of claim 1 , wherein the patient has macroalbuminuria.
11. The method of claim 1 , wherein prior to the onset of treatment with lixisenatide, the patient's type 2 diabetes mellitus is not adequately controlled.
12. The method of claim 1 , wherein the lixisenatide is administered subcutaneously.
13. The method of claim 1 , wherein the lixisenatide is administered in a daily dose of 5 μg to 20 μg.
14. The method of claim 11 , wherein the patient's type 2 diabetes mellitus is not adequately controlled on insulin or a pharmaceutically acceptable salt thereof.
15. The method of claim 1 , wherein the patient receives lixisenatide in combination with metformin or a pharmaceutically acceptable salt thereof.
16. The method of claim 1 , wherein the patient receives lixisenatide in combination with a glinide or a pharmaceutically acceptable salt thereof.
17. The method of claim 1 , wherein the patient receives lixisenatide in combination with a sulfonylurea or a pharmaceutically acceptable salt thereof.